A Prostate cancer patient story
Succesfully treated using the combination of Insulin Potentiation Low dose chemo plus homotoxicology
When I saw Mike at my office for the first time he had an invasive prostate cancer and the PSA was 180. Mike is a resident from Las Vegas,NV and decided to be treated by Dr. Donato Pérez García,M.D., with Insulin potentiation therapy low dose chemotherapy (IPTLD) and homotoxicology using a special protocol administered by Dr. Ricardo Duenas (Photo: Mike and Dr.Duenas) that compliments with the low dose chemo regimen. Mike's PSA has come down to normal levels and a recent CT scan showed a residual nodule not larger than 0.9 cc. There are no uncomfortable symptoms and he is doing his normal life. He comes every week to my office here in Tijuana,Mexico to receive his IPTLD treatment and returns to Las Vegas on the same day.
You can watch Mikes testimonial on the IPTLD Channel at YouTUBE
http://www.youtube.com/user/iptldonato#p/a/u/0/V4-ti5uOjcM
Mike's response to the combination program (IPTLD plus Homotoxicology) is considered very good based on his overall improvement and he is one of several patients treated with success of prostate cancer by Dr. Donato Pérez García,M.D.
The prostate is a chestnut-shaped gland of the male reproductive system and is about the size of a walnut. The prostate is located in front of the rectum and just below the bladder, and surrounds the beginning of the urethra (the tube that carries urine and semen out of the body).
The main purpose of the prostate is to produce fluid for semen, which transports sperm during the male orgasm, and to protect the bladder against bacterial invasion. The nerves involved in penile erection are located posteriorly on each side of the prostate gland. Therefore, the prostate is also considered to be an accessory sex organ.
The prostate normally increases in size around the age of puberty and then usually remains constant until the age of 45 to 50 years, at which time it may begin to undergo varying degrees of enlargement stimulated by rising levels of the male hormone testosterone. This non-cancer-related process is called benign prostatic hyperplasia and can cause urinary problems in older men. Approximately 33% of men over the age of 50 have benign prostatic hyperplasia .
The prostate can also develop cancer. Carcinoma of the prostate is the most commonly diagnosed male malignancy. It occurs when cells of the prostate mutate and begin to multiply uncontrollably Prostate cancer may cause pain, difficulty in urinating, problems during sexual intercourse, erectile dysfunction. Early detection is the key to successful treatment with a 5-year survival rate of greater than 80%. Many men who develop prostate cancer never have symptoms, undergo no therapy, and eventually die. This is because cancer of the prostate is, in most cases, slow-growing, and because most of those affected are from the age of 40-90. In its advanced stages, prostate cancer can spread (metastasize) to other parts of the body including the lymph nodes, bone, spine, liver, lungs, adrenal glands and the brain.
In general, prostate cancers grow slowly. It is known that the growth rate of prostate cancers increases in response to the presence of male hormones (androgens). Therefore, several treatments are targeted at reducing or eliminating androgens in the body.
Many factors, including genetics and diet, have been implicated in the development of prostate cancer. The presence of prostate cancer may be indicated by symptoms, physical examination, prostate specific antigen (PSA), or biopsy. There is concern about the accuracy of the PSA test and its usefulness in screening. Suspected prostate cancer is typically confirmed by taking a biopsy of the prostate and examining it under a microscope. Further tests, such as CT scans and bone scans, may be performed to determine whether prostate cancer has spread.
Treatment options for prostate cancer with intent to cure are primarily surgery and radiation therapy. Other treatments such as hormonal therapy, chemotherapy, proton therapy, cryosurgery, high intensity focused ultrasound (HIFU) also exist depending on the clinical scenario and desired outcome.
The age and underlying health of the man, the extent of metastasis, appearance under the microscope, and response of the cancer to initial treatment are important in determining the outcome of the disease. The decision whether or not to treat localized prostate cancer (a tumor that is contained within the prostate) with curative intent is a patient trade-off between the expected beneficial and harmful effects in terms of patient survival and quality of life.
Early prostate cancer usually causes no symptoms. Often it is diagnosed during the workup for an elevated PSA noticed during a routine checkup. Sometimes, however, prostate cancer does cause symptoms, often similar to those of diseases such as benign prostatic hypertrophy. These include frequent urination, increased urination at night, difficulty starting and maintaining a steady stream of urine, blood in the urine, and painful urination. Prostate cancer is associated with urinary dysfunction as the prostate gland surrounds the prostatic urethra. Changes within the gland therefore directly affect urinary function. Because the vas deferens deposits seminal fluid into the prostatic urethra, and secretions from the prostate gland itself are included in semen content, prostate cancer may also cause problems with sexual function and performance, such as difficulty achieving erection or painful ejaculation.[6]
The specific causes of prostate cancer remain unknown. A man's risk of developing prostate cancer is related to his age, genetics, race, diet, lifestyle, medications, and other factors.
A man's genetic background contributes to his risk of developing prostate cancer. Men who have a brother or father with prostate cancer have twice the usual risk of developing prostate cancer.
Dietary amounts of certain foods, vitamins, and minerals can contribute to prostate cancer risk. Synthetic vitamin A has been linked to prostate cancer because it reacts with zinc and protein to form an unabsorbable complex
There are also some links between prostate cancer and medications, medical procedures, and medical conditions. Daily use of anti-inflammatory medicines such as aspirin, ibuprofen, or naproxen may decrease prostate cancer risk. Use of the cholesterol-lowering drugs known as the statins may also decrease prostate cancer risk. Infection or inflammation of the prostate (prostatitis) may increase the chance for prostate cancer. In particular, infection with the sexually transmitted infections chlamydia, gonorrhea, or syphilis seems to increase risk. Finally, obesity and elevated blood levels of testosterona may increase the risk for prostate cancer.
Prostate cancer is classified as an adenocarcinoma, or glandular cancer, that begins when normal semen-secreting prostate gland cells mutate into cancer cells. The region of prostate gland where the adenocarcinoma is most common is the peripheral zone. Initially, small clumps of cancer cells remain confined to otherwise normal prostate glands, a condition known as carcinoma in situ or prostatic intraepithelial neoplasia. Over time these cancer cells begin to multiply and spread to the surrounding prostate tissue forming a tumor. Eventually, the tumor may grow large enough to invade nearby organs such as the seminal vesicles or the rectum, or the tumor cells may develop the ability to travel in the bloodstream and lymphatic system.
The only test which can fully confirm the diagnosis of prostate cancer is a biopsy, the removal of small pieces of the prostate for microscopic examination. However, prior to a biopsy, several other tools may be used to gather more information about the prostate and the urinary tract. Cystoscopy shows the urinary tract from inside the bladder, using a thin, flexible camera tube inserted down the urethra. Transrectal ultrasonography creates a picture of the prostate using sound waves from a probe in the rectum.
Evidence from epidemiological studies supports protective roles in reducing prostate cancer for dietary selenium, vitamin E, lycopene, and soy foods.
A 2007 study published in the Journal of the National Cancer Institute found that men eating cauliflower, broccoli, or one of the other cruciferous vegetables, more than once a week were 40% less likely to develop prostate cancer than men who rarely ate those vegetables.
Prostate cancer screening is an attempt to find unsuspected cancers. Prostate cancer screening options include the digital rectal exam and the prostate specific antigen (PSA) blood test. Screening for prostate cancer is controversial because it is not clear if the benefits of screening outweigh the risks of follow-up diagnostic tests and cancer treatments.
Convencional prostate cancer treatments like surgery, radiotherapy and in less proportion HIFU (high intensity focused ultrasound to ablate/destroy the tissue of the prostate) may cause urinary incontinence and impotence. (erectile dysfunction).
For cure or palliative care the treatment that has less or no side effects and cures is Insulin Potentiation Targeted Low Dose Therapy or IPTLD ® .
Succesfully treated using the combination of Insulin Potentiation Low dose chemo plus homotoxicology
When I saw Mike at my office for the first time he had an invasive prostate cancer and the PSA was 180. Mike is a resident from Las Vegas,NV and decided to be treated by Dr. Donato Pérez García,M.D., with Insulin potentiation therapy low dose chemotherapy (IPTLD) and homotoxicology using a special protocol administered by Dr. Ricardo Duenas (Photo: Mike and Dr.Duenas) that compliments with the low dose chemo regimen. Mike's PSA has come down to normal levels and a recent CT scan showed a residual nodule not larger than 0.9 cc. There are no uncomfortable symptoms and he is doing his normal life. He comes every week to my office here in Tijuana,Mexico to receive his IPTLD treatment and returns to Las Vegas on the same day.
You can watch Mikes testimonial on the IPTLD Channel at YouTUBE
http://www.youtube.com/user/iptldonato#p/a/u/0/V4-ti5uOjcM
Mike's response to the combination program (IPTLD plus Homotoxicology) is considered very good based on his overall improvement and he is one of several patients treated with success of prostate cancer by Dr. Donato Pérez García,M.D.
The prostate is a chestnut-shaped gland of the male reproductive system and is about the size of a walnut. The prostate is located in front of the rectum and just below the bladder, and surrounds the beginning of the urethra (the tube that carries urine and semen out of the body).
The main purpose of the prostate is to produce fluid for semen, which transports sperm during the male orgasm, and to protect the bladder against bacterial invasion. The nerves involved in penile erection are located posteriorly on each side of the prostate gland. Therefore, the prostate is also considered to be an accessory sex organ.
The prostate normally increases in size around the age of puberty and then usually remains constant until the age of 45 to 50 years, at which time it may begin to undergo varying degrees of enlargement stimulated by rising levels of the male hormone testosterone. This non-cancer-related process is called benign prostatic hyperplasia and can cause urinary problems in older men. Approximately 33% of men over the age of 50 have benign prostatic hyperplasia .
The prostate can also develop cancer. Carcinoma of the prostate is the most commonly diagnosed male malignancy. It occurs when cells of the prostate mutate and begin to multiply uncontrollably Prostate cancer may cause pain, difficulty in urinating, problems during sexual intercourse, erectile dysfunction. Early detection is the key to successful treatment with a 5-year survival rate of greater than 80%. Many men who develop prostate cancer never have symptoms, undergo no therapy, and eventually die. This is because cancer of the prostate is, in most cases, slow-growing, and because most of those affected are from the age of 40-90. In its advanced stages, prostate cancer can spread (metastasize) to other parts of the body including the lymph nodes, bone, spine, liver, lungs, adrenal glands and the brain.
In general, prostate cancers grow slowly. It is known that the growth rate of prostate cancers increases in response to the presence of male hormones (androgens). Therefore, several treatments are targeted at reducing or eliminating androgens in the body.
Many factors, including genetics and diet, have been implicated in the development of prostate cancer. The presence of prostate cancer may be indicated by symptoms, physical examination, prostate specific antigen (PSA), or biopsy. There is concern about the accuracy of the PSA test and its usefulness in screening. Suspected prostate cancer is typically confirmed by taking a biopsy of the prostate and examining it under a microscope. Further tests, such as CT scans and bone scans, may be performed to determine whether prostate cancer has spread.
Treatment options for prostate cancer with intent to cure are primarily surgery and radiation therapy. Other treatments such as hormonal therapy, chemotherapy, proton therapy, cryosurgery, high intensity focused ultrasound (HIFU) also exist depending on the clinical scenario and desired outcome.
The age and underlying health of the man, the extent of metastasis, appearance under the microscope, and response of the cancer to initial treatment are important in determining the outcome of the disease. The decision whether or not to treat localized prostate cancer (a tumor that is contained within the prostate) with curative intent is a patient trade-off between the expected beneficial and harmful effects in terms of patient survival and quality of life.
Early prostate cancer usually causes no symptoms. Often it is diagnosed during the workup for an elevated PSA noticed during a routine checkup. Sometimes, however, prostate cancer does cause symptoms, often similar to those of diseases such as benign prostatic hypertrophy. These include frequent urination, increased urination at night, difficulty starting and maintaining a steady stream of urine, blood in the urine, and painful urination. Prostate cancer is associated with urinary dysfunction as the prostate gland surrounds the prostatic urethra. Changes within the gland therefore directly affect urinary function. Because the vas deferens deposits seminal fluid into the prostatic urethra, and secretions from the prostate gland itself are included in semen content, prostate cancer may also cause problems with sexual function and performance, such as difficulty achieving erection or painful ejaculation.[6]
The specific causes of prostate cancer remain unknown. A man's risk of developing prostate cancer is related to his age, genetics, race, diet, lifestyle, medications, and other factors.
A man's genetic background contributes to his risk of developing prostate cancer. Men who have a brother or father with prostate cancer have twice the usual risk of developing prostate cancer.
Dietary amounts of certain foods, vitamins, and minerals can contribute to prostate cancer risk. Synthetic vitamin A has been linked to prostate cancer because it reacts with zinc and protein to form an unabsorbable complex
There are also some links between prostate cancer and medications, medical procedures, and medical conditions. Daily use of anti-inflammatory medicines such as aspirin, ibuprofen, or naproxen may decrease prostate cancer risk. Use of the cholesterol-lowering drugs known as the statins may also decrease prostate cancer risk. Infection or inflammation of the prostate (prostatitis) may increase the chance for prostate cancer. In particular, infection with the sexually transmitted infections chlamydia, gonorrhea, or syphilis seems to increase risk. Finally, obesity and elevated blood levels of testosterona may increase the risk for prostate cancer.
Prostate cancer is classified as an adenocarcinoma, or glandular cancer, that begins when normal semen-secreting prostate gland cells mutate into cancer cells. The region of prostate gland where the adenocarcinoma is most common is the peripheral zone. Initially, small clumps of cancer cells remain confined to otherwise normal prostate glands, a condition known as carcinoma in situ or prostatic intraepithelial neoplasia. Over time these cancer cells begin to multiply and spread to the surrounding prostate tissue forming a tumor. Eventually, the tumor may grow large enough to invade nearby organs such as the seminal vesicles or the rectum, or the tumor cells may develop the ability to travel in the bloodstream and lymphatic system.
The only test which can fully confirm the diagnosis of prostate cancer is a biopsy, the removal of small pieces of the prostate for microscopic examination. However, prior to a biopsy, several other tools may be used to gather more information about the prostate and the urinary tract. Cystoscopy shows the urinary tract from inside the bladder, using a thin, flexible camera tube inserted down the urethra. Transrectal ultrasonography creates a picture of the prostate using sound waves from a probe in the rectum.
Evidence from epidemiological studies supports protective roles in reducing prostate cancer for dietary selenium, vitamin E, lycopene, and soy foods.
A 2007 study published in the Journal of the National Cancer Institute found that men eating cauliflower, broccoli, or one of the other cruciferous vegetables, more than once a week were 40% less likely to develop prostate cancer than men who rarely ate those vegetables.
Prostate cancer screening is an attempt to find unsuspected cancers. Prostate cancer screening options include the digital rectal exam and the prostate specific antigen (PSA) blood test. Screening for prostate cancer is controversial because it is not clear if the benefits of screening outweigh the risks of follow-up diagnostic tests and cancer treatments.
Convencional prostate cancer treatments like surgery, radiotherapy and in less proportion HIFU (high intensity focused ultrasound to ablate/destroy the tissue of the prostate) may cause urinary incontinence and impotence. (erectile dysfunction).
For cure or palliative care the treatment that has less or no side effects and cures is Insulin Potentiation Targeted Low Dose Therapy or IPTLD ® .
No comments:
New comments are not allowed.